{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Migraine+With+or+Without+Aura&page=2",
    "query": {
      "condition": "Migraine With or Without Aura",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Migraine+With+or+Without+Aura&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T00:56:00.724Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02605174",
      "title": "Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine With or Without Aura"
      ],
      "interventions": [
        {
          "name": "Lasmiditan 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Lasmiditan 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Lasmiditan 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3005,
      "start_date": "2016-05",
      "completion_date": "2017-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-09-23",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 95,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605174"
    },
    {
      "nct_id": "NCT00610428",
      "title": "Staccato Prochlorperazine in Migraine (in Clinic)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine Headache, With or Without Aura"
      ],
      "interventions": [
        {
          "name": "Staccato Placebo",
          "type": "DRUG"
        },
        {
          "name": "Staccato Prochlorperazine 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Staccato Prochlorperazine 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 75,
      "start_date": "2005-03",
      "completion_date": "2005-10",
      "has_results": true,
      "last_update_posted_date": "2018-01-25",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 1,
      "location_summary": "Mount Vernon, New York",
      "locations": [
        {
          "city": "Mount Vernon",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00610428"
    },
    {
      "nct_id": "NCT00123201",
      "title": "Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine With Aura",
        "Migraine Without Aura"
      ],
      "interventions": [
        {
          "name": "Dronabinol MDI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solvay Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "2005-09",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2015-01-16",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 29,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00123201"
    },
    {
      "nct_id": "NCT03220113",
      "title": "Treatment of Chronic Migraine Headaches.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Migraine Without Aura, Intractable",
        "Migraine With Typical Aura",
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "Dexamethasone, Lidocaine, Thiamine cohort",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Corona Doctors Medical Clinics, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "10 Years to 90 Years"
      },
      "enrollment_count": 100,
      "start_date": "2017-07-01",
      "completion_date": "2019-07-01",
      "has_results": false,
      "last_update_posted_date": "2018-04-04",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 1,
      "location_summary": "Corona, California",
      "locations": [
        {
          "city": "Corona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220113"
    },
    {
      "nct_id": "NCT03061734",
      "title": "Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine With or Without Aura"
      ],
      "interventions": [
        {
          "name": "Naltrexone and Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone and Acetaminophen-High Dose",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone Alone (regular dose)",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen Alone",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allodynic Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2017-02-18",
      "completion_date": "2018-02-08",
      "has_results": false,
      "last_update_posted_date": "2021-04-14",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 1,
      "location_summary": "North Miami, Florida",
      "locations": [
        {
          "city": "North Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03061734"
    },
    {
      "nct_id": "NCT02848326",
      "title": "Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Migraine, With or Without Aura"
      ],
      "interventions": [
        {
          "name": "Atogepant",
          "type": "DRUG"
        },
        {
          "name": "Placebo-matching Atogepant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 834,
      "start_date": "2016-09-06",
      "completion_date": "2018-04-23",
      "has_results": true,
      "last_update_posted_date": "2018-12-06",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02848326"
    },
    {
      "nct_id": "NCT03006276",
      "title": "Efficacy, Tolerability, and Safety Study of DFN-15",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine Headache"
      ],
      "interventions": [
        {
          "name": "DFN-15 Active",
          "type": "DRUG"
        },
        {
          "name": "DFN-15 Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "BioDelivery Sciences International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 622,
      "start_date": "2016-12",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03006276"
    },
    {
      "nct_id": "NCT05127954",
      "title": "Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Ubrogepant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 1200,
      "start_date": "2022-01-14",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-20",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 109,
      "location_summary": "Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127954"
    },
    {
      "nct_id": "NCT05125302",
      "title": "Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Ubrogepant",
          "type": "DRUG"
        },
        {
          "name": "Placebo-Matching Ubrogepant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 1059,
      "start_date": "2022-01-13",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 120,
      "location_summary": "Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 99 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glenwood",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05125302"
    },
    {
      "nct_id": "NCT00792636",
      "title": "A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "sumatriptan and naproxen sodium combination tablet",
          "type": "DRUG"
        },
        {
          "name": "sumatriptan tablet",
          "type": "DRUG"
        },
        {
          "name": "naproxen sodium tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 407,
      "start_date": "2008-11",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2016-11-23",
      "last_synced_at": "2026-05-22T00:56:00.724Z",
      "location_count": 49,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00792636"
    }
  ]
}